108 related articles for article (PubMed ID: 31330078)
1. The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a control.
Grabarek B; Krzaczyński J; Strzałka-Mrozik B; Wcisło-Dziadecka D; Gola J
Dermatol Ther; 2019 Sep; 32(5):e13029. PubMed ID: 31330078
[TBL] [Abstract][Full Text] [Related]
2. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab.
Wcisło-Dziadecka DL; Grabarek B; Kruszniewska-Rajs C; Gola JM; Simka K; Mazurek U
Adv Clin Exp Med; 2020 Feb; 29(2):235-241. PubMed ID: 32125100
[TBL] [Abstract][Full Text] [Related]
4. Calcipotriol inhibits proliferation of human keratinocytes by downregulating STAT1 and STAT3 signaling.
Liang W; Lin Z; Zhang L; Qin X; Zhang Y; Sun L
J Investig Med; 2017 Feb; 65(2):376-381. PubMed ID: 28130440
[TBL] [Abstract][Full Text] [Related]
5. The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.
Wcisło-Dziadecka D; Grabarek B; Kruszniewska-Rajs C; Strzałka-Mrozik B
Dermatol Ther; 2019 May; 32(3):e12843. PubMed ID: 30693647
[TBL] [Abstract][Full Text] [Related]
6. 'Psoriasis 1' reduces psoriasis‑like skin inflammation by inhibiting the VDR‑mediated nuclear NF‑κB and STAT signaling pathways.
Sun W; Gao Y; Yu X; Yuan Y; Yi J; Zhang Z; Cheng Y; Li Y; Peng X; Cha X
Mol Med Rep; 2018 Sep; 18(3):2733-2743. PubMed ID: 30015892
[TBL] [Abstract][Full Text] [Related]
7. Associations between STAT Gene Polymorphisms and Psoriasis in Northeastern China.
Zhou J; Li Y; Sun D
Dermatology; 2017; 233(1):30-36. PubMed ID: 28420002
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of gene expression profiles identifies transcription factors potentially involved in psoriasis pathogenesis.
Zeng F; Liu H; Lu D; Liu Q; Chen H; Zheng F
J Cell Biochem; 2019 Aug; 120(8):12582-12594. PubMed ID: 30825251
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
10. Analysis of STAT1, STAT2 and STAT3 mRNA expression levels in the blood of patients with multiple sclerosis.
Manoochehrabadi S; Arsang-Jang S; Mazdeh M; Inoko H; Sayad A; Taheri M
Hum Antibodies; 2019; 27(2):91-98. PubMed ID: 30412483
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
12. Genome-Wide Association Study of Ustekinumab Response in Psoriasis.
Connell WT; Hong J; Liao W
Front Immunol; 2021; 12():815121. PubMed ID: 35154085
[TBL] [Abstract][Full Text] [Related]
13. STAT1 activation represses IL-22 gene expression and psoriasis pathogenesis.
Bai L; Fang H; Xia S; Zhang R; Li L; Ochando J; Xu J; Ding Y
Biochem Biophys Res Commun; 2018 Jun; 501(2):563-569. PubMed ID: 29750958
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.
Slattery ML; Lundgreen A; Hines LM; Torres-Mejia G; Wolff RK; Stern MC; John EM
Breast Cancer Res Treat; 2014 Aug; 147(1):145-58. PubMed ID: 25104439
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
[TBL] [Abstract][Full Text] [Related]
16. Expression of T-helper 17 cells and signal transducers in patients with psoriasis vulgaris of blood-heat syndrome and blood-stasis syndrome.
Fan B; Li X; Ze K; Xu R; Shi RF; Geng L; Li FL; Wang YF; Chen J; Li B
Chin J Integr Med; 2015 Jan; 21(1):10-6. PubMed ID: 25246139
[TBL] [Abstract][Full Text] [Related]
17. SOCS1-negative feedback of STAT1 activation is a key pathway in the dsRNA-induced innate immune response of human keratinocytes.
Dai X; Sayama K; Yamasaki K; Tohyama M; Shirakata Y; Hanakawa Y; Tokumaru S; Yahata Y; Yang L; Yoshimura A; Hashimoto K
J Invest Dermatol; 2006 Jul; 126(7):1574-81. PubMed ID: 16628196
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the roles of STAT1 and STAT3 signal transduction pathways in mammalian lens development.
Ebong S; Chepelinsky AB; Robinson ML; Zhao H; Yu CR; Egwuagu CE
Mol Vis; 2004 Feb; 10():122-31. PubMed ID: 14978477
[TBL] [Abstract][Full Text] [Related]
19. Abnormal regulation of fibronectin production by fibroblasts in psoriasis.
Gubán B; Vas K; Balog Z; Manczinger M; Bebes A; Groma G; Széll M; Kemény L; Bata-Csörgő Z
Br J Dermatol; 2016 Mar; 174(3):533-41. PubMed ID: 26471375
[TBL] [Abstract][Full Text] [Related]
20. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3.
Shen X; Hong F; Nguyen VA; Gao B
FEBS Lett; 2000 Sep; 480(2-3):132-6. PubMed ID: 11034314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
